Tredje AP fonden Has $104.53 Million Stake in Boston Scientific Corporation $BSX

Tredje AP fonden raised its stake in Boston Scientific Corporation (NYSE:BSX) by 24.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,070,688 shares of the medical equipment provider’s stock after acquiring an additional 210,000 shares during the quarter. Boston Scientific makes up approximately 0.8% of Tredje AP fonden’s investment portfolio, making the stock its 25th largest position. Tredje AP fonden’s holdings in Boston Scientific were worth $104,531,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new position in Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Edgewood Management LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $746,655,000. Parnassus Investments LLC grew its stake in shares of Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after buying an additional 2,899,653 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after acquiring an additional 2,823,744 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research reports. Needham & Company LLC reduced their price objective on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus cut their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Truist Financial lowered their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Finally, TD Cowen cut their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Price Performance

Shares of BSX opened at $74.54 on Friday. The business has a 50-day moving average of $89.23 and a 200-day moving average of $96.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 0.96. The company has a market capitalization of $110.61 billion, a price-to-earnings ratio of 38.42, a price-to-earnings-growth ratio of 1.05 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.